SCHEMBL5962234

SCHEMBL5962234

CCOC(=O)c1cn(C[C@H]2CCN(C(=O)OC(C)(C)C)C2)c2cnc(Br)cc2c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.42
IDO1 P14902 1/20 0.41
TDO2 P48775 1/20 0.41
HPGD P15428 5/20 0.41
TP53 P04637 1/20 0.40
POLB P06746 1/20 0.40
ALDH1A1 P00352 4/20 0.40
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
GAA P10253 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MAPT P10636 2/20 0.39
THRB P10828 1/20 0.39
GPR119 Q8TDV5 1/20 0.38
KDM4E B2RXH2 3/20 0.38
HSD17B10 Q99714 2/20 0.38
USP7 Q93009 1/20 0.38
PIK3CD O00329 1/20 0.36
PIK3CA P42336 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5962236 1.00 LMNA (0.42) LMNAIDO1TDO2HPGDTP53
SCHEMBL13008046 0.85 HPGD (0.49) LMNAHPGDTP53POLBALDH1A1
SCHEMBL5962255 0.85 LMNA (0.48) LMNAHPGDPOLBALDH1A1KMT2A
SCHEMBL1430353 0.84 HPGD (0.47) LMNAHPGDTP53POLBALDH1A1
SCHEMBL13080498 0.84 HPGD (0.47) LMNAHPGDTP53POLBALDH1A1
SCHEMBL5962239 0.83 LMNA (0.44) LMNAHPGDPOLBALDH1A1KMT2A
SCHEMBL6033107 0.82 TP53 (0.38) LMNAHPGDTP53POLBALDH1A1
SCHEMBL6033352 0.82 TP53 (0.38) LMNAHPGDTP53POLBALDH1A1
SCHEMBL13045992 0.79 HPGD (0.44) LMNAHPGDALDH1A1KMT2AMEN1
SCHEMBL13045993 0.79 HPGD (0.44) LMNAHPGDALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8569484-B2 Heterocyclic urea derivatives and methods of use thereof ASTRAZENECA AB (SE) 2013-10-29 US disclosed
US-8569484-B2 Heterocyclic urea derivatives and methods of use thereof ASTRAZENECA AB (SE) 2013-10-29 US disclosed
US-20120122817-A1 HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2012-05-17 US disclosed
US-20120122817-A1 HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2012-05-17 US disclosed
WO-2010136817-A1 HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122817-A1 HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF UROD, UMPS, SLC14A1 LMNA 2498/4885IDO1 1235/4885TDO2 2658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.